A detailed history of Legal & General Group PLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Legal & General Group PLC holds 171,286 shares of IONS stock, worth $6.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
171,286
Previous 171,286 -0.0%
Holding current value
$6.26 Million
Previous $6.86 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.06 - $51.86 $386,298 - $500,085
9,643 Added 5.97%
171,286 $6.86 Million
Q2 2024

Aug 14, 2024

BUY
$36.45 - $47.7 $443,049 - $579,793
12,155 Added 8.13%
161,643 $7.7 Million
Q1 2024

Jul 01, 2024

BUY
$42.03 - $53.55 $491,330 - $625,999
11,690 Added 8.48%
149,488 $6.48 Million
Q1 2024

May 14, 2024

SELL
$42.03 - $53.55 $737,626 - $939,802
-17,550 Reduced 11.3%
137,798 $5.97 Million
Q4 2023

Feb 15, 2024

SELL
$43.39 - $51.63 $420,318 - $500,139
-9,687 Reduced 5.87%
155,348 $7.86 Million
Q3 2023

Nov 14, 2023

BUY
$38.5 - $47.13 $1.22 Million - $1.49 Million
31,692 Added 23.77%
165,035 $7.49 Million
Q2 2023

Aug 14, 2023

SELL
$34.73 - $43.33 $256,133 - $319,558
-7,375 Reduced 5.24%
133,343 $5.47 Million
Q1 2023

May 15, 2023

BUY
$33.58 - $41.2 $457,695 - $561,556
13,630 Added 10.72%
140,718 $5.03 Million
Q4 2022

Feb 14, 2023

SELL
$37.12 - $46.52 $50,668 - $63,499
-1,365 Reduced 1.06%
127,088 $4.8 Million
Q3 2022

Nov 14, 2022

SELL
$36.54 - $48.66 $1.3 Million - $1.73 Million
-35,501 Reduced 21.65%
128,453 $5.68 Million
Q2 2022

Aug 22, 2022

BUY
$31.71 - $43.0 $51,877 - $70,348
1,636 Added 1.01%
163,954 $6.07 Million
Q1 2022

May 16, 2022

BUY
$29.88 - $37.04 $118,743 - $147,196
3,974 Added 2.51%
162,318 $6.01 Million
Q4 2021

Feb 14, 2022

SELL
$25.61 - $35.1 $232,461 - $318,602
-9,077 Reduced 5.42%
158,344 $4.82 Million
Q3 2021

Nov 15, 2021

BUY
$33.54 - $40.55 $1.39 Million - $1.68 Million
41,538 Added 33.0%
167,421 $5.62 Million
Q2 2021

Aug 12, 2021

SELL
$34.54 - $47.25 $10.2 Million - $13.9 Million
-294,494 Reduced 70.05%
125,883 $5.02 Million
Q1 2021

May 17, 2021

SELL
$42.51 - $63.78 $1.93 Million - $2.89 Million
-45,321 Reduced 9.73%
420,377 $18.9 Million
Q4 2020

Feb 12, 2021

BUY
$45.3 - $60.27 $1.41 Million - $1.88 Million
31,193 Added 7.18%
465,698 $26.3 Million
Q3 2020

Nov 13, 2020

SELL
$47.45 - $62.95 $874,883 - $1.16 Million
-18,438 Reduced 4.07%
434,505 $20.6 Million
Q2 2020

Aug 14, 2020

BUY
$46.85 - $61.05 $838,849 - $1.09 Million
17,905 Added 4.12%
452,943 $26.7 Million
Q1 2020

May 14, 2020

BUY
$41.6 - $63.4 $1.18 Million - $1.8 Million
28,404 Added 6.99%
435,038 $20.6 Million
Q4 2019

Feb 13, 2020

BUY
$53.85 - $65.27 $882,386 - $1.07 Million
16,386 Added 4.2%
406,634 $24.6 Million
Q3 2019

Nov 13, 2019

BUY
$59.06 - $72.15 $2.04 Million - $2.49 Million
34,465 Added 9.69%
390,248 $23.4 Million
Q2 2019

Aug 14, 2019

BUY
$62.09 - $86.14 $17.6 Million - $24.4 Million
283,306 Added 390.89%
355,783 $22.9 Million
Q1 2019

May 15, 2019

BUY
$52.92 - $81.17 $100,600 - $154,304
1,901 Added 2.69%
72,477 $5.88 Million
Q4 2018

Feb 15, 2019

BUY
$43.37 - $59.54 $375,280 - $515,199
8,653 Added 13.97%
70,576 $3.82 Million
Q3 2018

Nov 20, 2018

BUY
$42.88 - $53.7 $130,440 - $163,355
3,042 Added 5.17%
61,923 $3.19 Million
Q2 2018

Aug 10, 2018

SELL
$40.53 - $50.7 $387,912 - $485,249
-9,571 Reduced 13.98%
58,881 $2.45 Million
Q1 2018

May 17, 2018

BUY
$44.08 - $55.05 $84,854 - $105,971
1,925 Added 2.89%
68,452 $3.02 Million
Q4 2017

Feb 13, 2018

BUY
$50.3 - $64.39 $3.35 Million - $4.28 Million
66,527
66,527 $3.35 Million

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.19B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.